ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded up 30.3% during mid-day trading on Friday . The stock traded as high as GBX 5.70 ($0.07) and last traded at GBX 5.08 ($0.06). 14,823,431 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 21,654,844 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Price Performance
The business’s 50 day simple moving average is GBX 2.39 and its 200 day simple moving average is GBX 1.93. The stock has a market cap of £19.99 million, a P/E ratio of -480.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Options Trading – Understanding Strike Price
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- 3 Tickers Leading a Meme Stock Revival
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
